TLDR:
Key points:
- Inheart, a medical device company based in Pessac, France, raised USD11M in funding led by Vesalius Biocapital IV and co-led by Elaia Partners.
- The company plans to expand its digital twin of the heart in various markets and develop new software solutions for cardiac care.
Inheart, a medical device company based in Pessac, France, has raised USD11M in funding from a variety of investors including Vesalius Biocapital IV and Elaia Partners. Other participants in the funding round included NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In addition, inheart also received funds from a crowdequity campaign on Tudigo and from the UK impact fund Astorg Foundation.
The funds will be used to support the commercial expansion of inheart’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets. The company also plans to develop new software solutions to enhance cardiac care across the continuum. Inheart, led by CEO Todor Jeliaskov, aims to deliver AI-driven personalized therapy for patients living with cardiac diseases, focusing on screening and early detection.
Todor Jeliaskov expressed excitement about the potential impact of the new funding, stating, “This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support. It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.”
